SDZ on Swiss Stock Exchange

Sandoz

Logo: Sandoz AG, Public domain, via Wikimedia Commons3

Swiss pharmaceuticals and biosimilars company

Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz.2 From Wikipedia, CC BY-SA 4.0

Price unavailable

Last updated Oct 16, 2026.

Overview

1886Founded1

Compare with another stock.

  • TickerSDZ on Swiss Stock Exchange1
  • Industrychemical industry, pharmaceutical industry1
  • HeadquartersBasel1
  • Websitewww.sandoz.com
  • Legal formAktiengesellschaft1

Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz. Before this, the company existed as an independent pharmaceutical manufacturer until 1996, when it was merged with Ciba-Geigy to form Novartis. Prior to the merger, it specialized in medicines used in organ transplants, such as Sandimmune, and various antipsychotics and migraine medicines. Its headquarters were in Holzkirchen, Germany and after the spin-off from Novartis, the headquarters moved to Basel, Switzerland, with most of global functions operating from Holzkirchen in Germany, Prague in Czechia, and Barcelona in Spain. Sandoz is the global leader in generic pharmaceuticals and biosimilars.2

How it started

1886–1995: Formation and initial growth

The company was founded in 1886 by Alfred Kern (1850–1893) and Edouard Sandoz (1853–1928) in Basel (Switzerland) under the name Chemiefirma Kern und Sandoz. Initially the company focused on production of dyes namely alizarin blue and auramine. When Kern died, the company changed its name to Chemische Fabrik vormals Sandoz in 1895 and began producing pharmaceuticals for the first time the same year. As early as 1895, the first pharmaceutical substance called antipyrine was produced to reduce fever. In 1899 they started producing saccharin.

In 1917, Sandoz entered pharmaceutical research when Arthur Stoll (1887–1971) was hired, and, in 1929, Calcium Sandoz was introduced, laying the foundation research into modern calcium therapy.

In 1918, Arthur Stoll isolated ergotamine from ergot; the substance was eventually used to treat migraine and headaches and was introduced under the trade name Gynergen in 1921.

In 1938 Albert Hofmann produced the synthetic substance lysergic acid diethylamide, better known as LSD. The psychoactive properties of this preparation were nevertheless not discovered until 1943, when Hofmann ingested a small amount by accident. From 1947 to the mid-60s, LSD was sold by Sandoz under the name Delysid. It was marketed as a treatment for a wide variety of mental ailments, ranging from alcoholism to sexual deviancy. Sandoz suggested in its marketing literature that psychiatrists take LSD themselves, to gain a better subjective understanding of the schizophrenic experience, and many did exactly that and so did other scientific researchers. The Sandoz product received mass publicity as early as 1954, in a Time magazine feature. Research on LSD peaked in the 1950s and early 1960s. The CIA purchased quantities of LSD from Sandoz for use in its illegal human experimentation program known as MKUltra. Sandoz withdrew the drug from the market in 1965. The drug became a cultural novelty of the 1960s after psychologist Timothy Leary at Harvard University began to promote its use for recreational and spiritual experiences among the general public.

In 1939, Kern & Sandoz became Sandoz Ltd., a name it operated under for nearly sixty years.

From Wikipedia’s article on Sandoz, shared under CC BY-SA 4.0.2

Products and brands

  • generic drug

Listed on Wikidata.1

Subsidiaries and ownership

Subsidiaries

  • Lek
  • Hexal AG since Feb 2005

Also owns

  • Lab'O

Former owners and parents

From Wikidata.1

Acquisitions

  1. Feb 2005Acquired Hexal AG1

Employees over time

  • 20235,7241

Revenue over time

As stated on Wikidata, in the currency reported.

Revenue

  • 2022$9.2B1

Timeline

  1. Oct 5, 2023Went public Listed on Swiss Stock Exchange1
  2. 1886Founded Founded1

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3